Moderate Exercise for Nonalcoholic Fatty Liver Disease

Prenner, Stacey; Rinella, Mary E.

doi:10.1001/jamainternmed.2016.3221

Cited by 7 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biomarkers of liver damage may allow specific COPD endotypes to be detected, leading to personalised treatments [36]. As physical activity is the first-line treatment of NAFLD [50][51][52], pulmonary rehabilitation could be expected to have a positive effect on NAFLD in COPD patients. In the obese inflamed COPD phenotype, lifestyle intervention with cautious weight loss might also improve NAFLD.…”

Section: Discussionmentioning

confidence: 99%

Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease

et al. 2017

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and mortality. Low-grade inflammation, oxidative stress and ectopic fat, common features of chronic obstructive pulmonary disease (COPD), might contribute to the development of NAFLD.We aimed to investigate the prevalence of NAFLD and to evaluate the relationship between various types of liver damage and COPD severity, comorbidities and circulating inflammatory cytokines. Validated noninvasive tests (FibroMax: SteatoTest, NashTest and FibroTest) were used to assess steatosis, nonalcoholic steatohepatitis (NASH) and liver fibrosis. Patients underwent an objective assessment of COPD comorbidities, including sleep studies. Biological parameters included a complete lipid profile and inflammatory markers.In COPD patients the prevalence of steatosis, NASH and fibrosis were 41.4%, 36.9% and 61.3%, respectively. In multivariate analysis, SteatoTest and FibroTest were significantly associated with sex, body mass index (BMI), untreated sleep apnoea and insulin resistance, and, in addition, COPD Global Initiative for Chronic Obstructive Lung Disease stage for SteatoTest. Patients with steatosis had higher tumour necrosis factor-α levels and those with NASH or a combination of liver damage types had raised leptin levels after adjustment for age, sex and BMI.We concluded that NAFLD is highly prevalent in COPD and might contribute to cardiometabolic comorbidities.

show abstract

Section: Discussionmentioning

confidence: 99%

Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…HBV infection is well manageable whereas HCV infection (before the DAA era) would have been progressive after resection or destruction. NAFLD is associated with obesity and diabetes and both can potentially lead to serious comorbidity [25], and alcohol abuse may have continued or recurred. Differences in etiology of underlying liver disease or (their impact on) comorbidity as contributors to the observed survival disparities after resection could not be studied since these data were not present in our database.…”

Section: Discussionmentioning

confidence: 99%

Factors associated with ethnical disparity in overall survival for patients with hepatocellular carcinoma

Hansen

Peppelenbosch

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is an important cause of cancer-related death worldwide. Ethnical disparity in overall survival has been demonstrated for HCC patients in the United States (U.S.). We aimed to evaluate the contributors to this survival disparity. The SEER database was used to identify HCC patients from 2004 to 2012. Kaplan-Meier curves and Cox proportional hazard models were used to evaluate overall survival by ethnicity and the contributors to ethnical survival disparity. A total of 33 062 patients were included: 15 986 Non-Hispanic Whites, 6535 Hispanic Whites, 4842 African Americans, and 5699 Asians. Compared to Non-Hispanic Whites, African Americans had worse survival (HR, 1.18; 95%CI, 1.14–1.23), while Asians had a better survival (HR, 0.85; 95%CI, 0.82–0.89), and Hispanic Whites had a similar survival (HR, 1.01; 95%CI, 0.97–1.05). Multivariate Cox analysis identified that tumor presentation- and treatment-related factors significantly contributed to the ethnical survival disparity. Especially, tumor size was the most important contributor (HR, 1.11; 95%CI, 1.07–1.16). There is no ethnical survival disparity in patients undergoing liver transplantation and sub-analysis of patients within the Milan criteria for liver transplantation demonstrated no significant survival disparity between African Americans and non-Hispanic Whites in transplantation adjustment analysis (HR, 1.23; 95%CI, 1.11–1.35 in non-adjustment analysis to HR, 1.05; 95%CI, 0.95–1.15 after adjustment). Finally, no important contributor to the superior overall survival in Asians was identified. In conclusion, poor tumor presentation at diagnosis, limited benefit from resection and restricted utilization of liver transplantation are important contributors to poorer survival of African Americans with HCC.

show abstract

“…The cornerstone of NAFLD treatment is lifestyle intervention [16]. Physical activity should be implemented [216,217], aiming at a minimum of 150–200 min/week of moderate intensity aerobic physical activity; a dose-effect relationship has been demonstrated, pointing out that high intensity exercise should be preferred to moderate exercise whenever possible [1]. However, the most effective strategy to reduce liver fat is dietary restriction, thus the European guidelines recommend a 7–10% weight loss (“weight normative” approach) [1,218].…”

Section: Therapymentioning

confidence: 99%

Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview

Marchisello

Pino

Purrello

et al. 2019

IJMS

156

140

View full text Add to dashboard Cite

Nonalcoholic Fatty Liver Disease (NAFLD) represents the leading cause of liver disease in developed countries but its diffusion is currently also emerging in Asian countries, in South America and in other developing countries. It is progressively becoming one of the main diseases responsible for hepatic insufficiency, hepatocarcinoma and the need for orthotopic liver transplantation. NAFLD is linked with metabolic syndrome in a close and bidirectional relationship. To date, NAFLD is a diagnosis of exclusion, and liver biopsy is the gold standard for diagnosis. NAFLD pathogenesis is complex and multifactorial, mainly involving genetic, metabolic and environmental factors. New concepts are constantly arising in the literature promising new diagnostic and therapeutic tools. One of the challenges will be to better characterize not only NAFLD development but overall NAFLD progression, in order to better identify NAFLD patients at higher risk of metabolic, cardiovascular and neoplastic complications. This review analyses NAFLD epidemiology and the different prevalence of the disease in distinct groups, particularly according to sex, age, body mass index, type 2 diabetes and dyslipidemia. Furthermore, the work expands on the pathophysiology of NAFLD, examining multiple-hit pathogenesis and the role of different factors in hepatic steatosis development and progression: genetics, metabolic factors and insulin resistance, diet, adipose tissue, gut microbiota, iron deposits, bile acids and circadian clock. In conclusion, the current available therapies for NAFLD will be discussed.

show abstract

Moderate Exercise for Nonalcoholic Fatty Liver Disease

Cited by 7 publications

References 7 publications

Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease

Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease

Factors associated with ethnical disparity in overall survival for patients with hepatocellular carcinoma

Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview

Contact Info

Product

Resources

About